David Barton
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Viral | 41 | 2025 | 690 | 6.550 |
Why?
| | Poliovirus | 31 | 2025 | 73 | 5.640 |
Why?
| | Brain Injuries, Traumatic | 9 | 2025 | 443 | 2.890 |
Why?
| | Virus Replication | 19 | 2025 | 537 | 2.880 |
Why?
| | Viral Proteins | 12 | 2025 | 365 | 2.550 |
Why?
| | Endoribonucleases | 9 | 2014 | 80 | 2.160 |
Why?
| | Recombination, Genetic | 4 | 2025 | 202 | 1.870 |
Why?
| | HeLa Cells | 28 | 2020 | 653 | 1.410 |
Why?
| | Picornaviridae | 3 | 2020 | 18 | 1.370 |
Why?
| | Ribavirin | 3 | 2020 | 71 | 1.210 |
Why?
| | Enterovirus C, Human | 2 | 2025 | 2 | 1.200 |
Why?
| | Snake Bites | 2 | 2019 | 24 | 1.140 |
Why?
| | Blepharoptosis | 1 | 2025 | 11 | 0.890 |
Why?
| | Blood-Brain Barrier | 2 | 2024 | 155 | 0.880 |
Why?
| | Multiple Organ Failure | 1 | 2025 | 125 | 0.870 |
Why?
| | Viral Nonstructural Proteins | 3 | 2020 | 67 | 0.830 |
Why?
| | Hepacivirus | 6 | 2014 | 232 | 0.830 |
Why?
| | Polyadenylation | 2 | 2015 | 41 | 0.800 |
Why?
| | Agkistrodon | 2 | 2023 | 6 | 0.780 |
Why?
| | Nucleic Acid Conformation | 11 | 2010 | 711 | 0.770 |
Why?
| | Emergency Medical Services | 2 | 2023 | 685 | 0.750 |
Why?
| | Air Ambulances | 1 | 2023 | 57 | 0.740 |
Why?
| | Sinusitis | 1 | 2025 | 237 | 0.720 |
Why?
| | RNA | 5 | 2020 | 940 | 0.680 |
Why?
| | Drug Resistance, Viral | 3 | 2020 | 119 | 0.670 |
Why?
| | Murine hepatitis virus | 1 | 2020 | 16 | 0.660 |
Why?
| | Protein Biosynthesis | 12 | 2008 | 454 | 0.630 |
Why?
| | Antiviral Agents | 5 | 2020 | 743 | 0.620 |
Why?
| | Hypogonadism | 2 | 2020 | 93 | 0.620 |
Why?
| | Heart Arrest | 1 | 2024 | 403 | 0.610 |
Why?
| | Hydrocortisone | 1 | 2021 | 305 | 0.600 |
Why?
| | Coral Snakes | 1 | 2019 | 3 | 0.590 |
Why?
| | RNA, Messenger | 7 | 2008 | 2847 | 0.580 |
Why?
| | Bupivacaine | 1 | 2018 | 38 | 0.560 |
Why?
| | Polyribosomes | 2 | 2008 | 22 | 0.560 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2782 | 0.520 |
Why?
| | Amino Acid Substitution | 5 | 2020 | 304 | 0.510 |
Why?
| | Nerve Block | 1 | 2018 | 100 | 0.510 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1525 | 0.490 |
Why?
| | Viral Core Proteins | 3 | 2003 | 22 | 0.490 |
Why?
| | RNA Stability | 4 | 2014 | 116 | 0.490 |
Why?
| | Base Sequence | 14 | 2012 | 2186 | 0.480 |
Why?
| | Leucine | 1 | 2016 | 116 | 0.470 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 451 | 0.460 |
Why?
| | Humans | 56 | 2025 | 143822 | 0.430 |
Why?
| | Ribonuclease, Pancreatic | 1 | 2014 | 12 | 0.420 |
Why?
| | RNA Cleavage | 1 | 2014 | 10 | 0.420 |
Why?
| | Templates, Genetic | 3 | 2010 | 62 | 0.410 |
Why?
| | Influenza A virus | 1 | 2014 | 112 | 0.410 |
Why?
| | Neurofilament Proteins | 2 | 2024 | 64 | 0.410 |
Why?
| | Wounds and Injuries | 3 | 2025 | 949 | 0.390 |
Why?
| | DNA-Directed RNA Polymerases | 3 | 2020 | 63 | 0.390 |
Why?
| | Molecular Sequence Data | 11 | 2012 | 2914 | 0.390 |
Why?
| | Pain | 1 | 2018 | 776 | 0.380 |
Why?
| | Transcription, Genetic | 7 | 2015 | 1504 | 0.380 |
Why?
| | Uridine | 2 | 2009 | 30 | 0.380 |
Why?
| | Biomarkers | 4 | 2025 | 4248 | 0.380 |
Why?
| | Poly U | 2 | 2010 | 3 | 0.360 |
Why?
| | Genome, Viral | 5 | 2025 | 222 | 0.350 |
Why?
| | Poly A | 2 | 2010 | 50 | 0.350 |
Why?
| | Host-Pathogen Interactions | 1 | 2014 | 372 | 0.350 |
Why?
| | Conserved Sequence | 2 | 2008 | 243 | 0.330 |
Why?
| | Cysteine Endopeptidases | 2 | 2008 | 74 | 0.330 |
Why?
| | Young Adult | 9 | 2025 | 13915 | 0.330 |
Why?
| | Poly C | 2 | 2008 | 2 | 0.330 |
Why?
| | Ribosomes | 2 | 2004 | 191 | 0.330 |
Why?
| | Open Reading Frames | 2 | 2008 | 133 | 0.310 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2009 | 13 | 0.310 |
Why?
| | Mutation | 9 | 2020 | 4106 | 0.300 |
Why?
| | Enterovirus | 2 | 2012 | 83 | 0.290 |
Why?
| | Glasgow Outcome Scale | 2 | 2025 | 14 | 0.290 |
Why?
| | Alcohol Drinking | 1 | 2016 | 831 | 0.290 |
Why?
| | Male | 19 | 2025 | 71570 | 0.280 |
Why?
| | Eukaryotic Initiation Factor-4G | 1 | 2008 | 6 | 0.280 |
Why?
| | Adult | 14 | 2025 | 40130 | 0.280 |
Why?
| | Pain Management | 2 | 2025 | 399 | 0.280 |
Why?
| | Uridine Monophosphate | 2 | 2008 | 14 | 0.270 |
Why?
| | Base Composition | 1 | 2007 | 79 | 0.260 |
Why?
| | Dinucleoside Phosphates | 1 | 2007 | 31 | 0.260 |
Why?
| | Glasgow Coma Scale | 2 | 2024 | 214 | 0.250 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1135 | 0.240 |
Why?
| | Middle Aged | 11 | 2025 | 35631 | 0.230 |
Why?
| | Sufentanil | 1 | 2025 | 3 | 0.230 |
Why?
| | Mutagenesis, Site-Directed | 3 | 2016 | 379 | 0.220 |
Why?
| | Ribonucleases | 1 | 2004 | 49 | 0.220 |
Why?
| | Intracranial Hemorrhage, Traumatic | 1 | 2024 | 10 | 0.220 |
Why?
| | Dendritic Spines | 2 | 2016 | 69 | 0.210 |
Why?
| | Kinetics | 5 | 2008 | 1622 | 0.210 |
Why?
| | RNA, Ribosomal | 3 | 2014 | 165 | 0.200 |
Why?
| | Aged | 9 | 2025 | 25616 | 0.200 |
Why?
| | Protein Binding | 5 | 2020 | 2261 | 0.200 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 408 | 0.200 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 206 | 0.190 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2025 | 184 | 0.190 |
Why?
| | Opiate Substitution Treatment | 1 | 2025 | 174 | 0.190 |
Why?
| | Prospective Studies | 5 | 2025 | 7900 | 0.190 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2023 | 59 | 0.190 |
Why?
| | 5' Untranslated Regions | 4 | 2012 | 60 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 127 | 0.190 |
Why?
| | Anaphylaxis | 1 | 2023 | 102 | 0.180 |
Why?
| | Uridine Triphosphate | 1 | 2001 | 9 | 0.180 |
Why?
| | Hepatitis C | 1 | 2004 | 249 | 0.180 |
Why?
| | Cell-Free System | 5 | 2008 | 53 | 0.180 |
Why?
| | Buprenorphine | 1 | 2025 | 182 | 0.180 |
Why?
| | Trauma Centers | 1 | 2024 | 462 | 0.180 |
Why?
| | Protein Conformation | 3 | 2015 | 933 | 0.170 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.170 |
Why?
| | Animals | 12 | 2023 | 38140 | 0.170 |
Why?
| | Models, Molecular | 4 | 2015 | 1600 | 0.160 |
Why?
| | Plasmids | 4 | 2008 | 376 | 0.160 |
Why?
| | Nucleotide Motifs | 1 | 2020 | 36 | 0.160 |
Why?
| | Enterovirus B, Human | 1 | 2020 | 25 | 0.160 |
Why?
| | Female | 10 | 2025 | 77571 | 0.160 |
Why?
| | Computational Biology | 1 | 2025 | 683 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 337 | 0.160 |
Why?
| | Sindbis Virus | 2 | 1991 | 10 | 0.160 |
Why?
| | Carrier Proteins | 2 | 2009 | 750 | 0.160 |
Why?
| | Picornaviridae Infections | 1 | 2020 | 50 | 0.160 |
Why?
| | Pituitary Gland | 1 | 2020 | 153 | 0.150 |
Why?
| | Brain Injuries | 2 | 2016 | 506 | 0.150 |
Why?
| | Hypothalamus | 1 | 2020 | 156 | 0.150 |
Why?
| | Ribonuclease T1 | 2 | 2009 | 5 | 0.150 |
Why?
| | Injury Severity Score | 3 | 2024 | 598 | 0.150 |
Why?
| | Mutation, Missense | 2 | 2019 | 342 | 0.150 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2009 | 97 | 0.140 |
Why?
| | Fascia | 1 | 2018 | 18 | 0.140 |
Why?
| | Femoral Nerve | 1 | 2018 | 19 | 0.140 |
Why?
| | Guanidine | 3 | 2009 | 20 | 0.140 |
Why?
| | Apolipoprotein E4 | 1 | 2018 | 39 | 0.140 |
Why?
| | Injections | 1 | 2018 | 194 | 0.140 |
Why?
| | Cohort Studies | 3 | 2024 | 5862 | 0.140 |
Why?
| | Anesthetics, Local | 1 | 2018 | 101 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2008 | 2148 | 0.130 |
Why?
| | Mice | 7 | 2020 | 18421 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2025 | 582 | 0.130 |
Why?
| | Models, Genetic | 3 | 2008 | 533 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2020 | 511 | 0.130 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 6032 | 0.130 |
Why?
| | Neuropsychological Tests | 2 | 2024 | 1122 | 0.120 |
Why?
| | Peptide Initiation Factors | 1 | 1996 | 17 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2025 | 16755 | 0.120 |
Why?
| | Nucleotides | 2 | 2008 | 126 | 0.120 |
Why?
| | Alcohols | 1 | 2016 | 28 | 0.120 |
Why?
| | Registries | 1 | 2024 | 2242 | 0.120 |
Why?
| | Administration, Sublingual | 2 | 2025 | 12 | 0.120 |
Why?
| | Cell Line | 4 | 2014 | 2906 | 0.110 |
Why?
| | Binding, Competitive | 2 | 2008 | 192 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 371 | 0.110 |
Why?
| | Risk Assessment | 1 | 2024 | 3556 | 0.110 |
Why?
| | Time Factors | 5 | 2025 | 7068 | 0.110 |
Why?
| | DNA, Complementary | 2 | 2008 | 278 | 0.110 |
Why?
| | Hydrolysis | 1 | 2014 | 199 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 5761 | 0.110 |
Why?
| | RNA Precursors | 1 | 1995 | 157 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1901 | 0.100 |
Why?
| | RNA, Small Nuclear | 1 | 2014 | 38 | 0.100 |
Why?
| | White Matter | 1 | 2016 | 150 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 337 | 0.100 |
Why?
| | Genetic Complementation Test | 3 | 2004 | 67 | 0.100 |
Why?
| | Sulfur Radioisotopes | 2 | 2008 | 13 | 0.100 |
Why?
| | RNA, Double-Stranded | 2 | 2004 | 58 | 0.100 |
Why?
| | Binding Sites | 2 | 2008 | 1312 | 0.100 |
Why?
| | Cells, Cultured | 1 | 2020 | 4172 | 0.090 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 857 | 0.090 |
Why?
| | Macrophages | 1 | 2020 | 1508 | 0.090 |
Why?
| | Autoantibodies | 1 | 2020 | 1497 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 426 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3834 | 0.090 |
Why?
| | Patient Care Management | 1 | 2012 | 55 | 0.090 |
Why?
| | Emergency Medical Technicians | 1 | 2012 | 44 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5317 | 0.090 |
Why?
| | Argonaute Proteins | 1 | 2012 | 28 | 0.090 |
Why?
| | West Nile virus | 1 | 2012 | 40 | 0.090 |
Why?
| | Adolescent | 5 | 2021 | 22234 | 0.090 |
Why?
| | West Nile Fever | 1 | 2012 | 56 | 0.090 |
Why?
| | Immune Evasion | 1 | 2012 | 66 | 0.090 |
Why?
| | Semliki forest virus | 1 | 1991 | 2 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 559 | 0.080 |
Why?
| | Alphavirus | 1 | 1991 | 22 | 0.080 |
Why?
| | Genes, Viral | 1 | 1991 | 92 | 0.080 |
Why?
| | Amyloid beta-Peptides | 1 | 2013 | 236 | 0.080 |
Why?
| | Physical Examination | 1 | 2012 | 235 | 0.080 |
Why?
| | Interferon Type I | 1 | 2012 | 144 | 0.080 |
Why?
| | RNA, Untranslated | 1 | 2012 | 123 | 0.080 |
Why?
| | Logistic Models | 1 | 2016 | 2095 | 0.080 |
Why?
| | Temperature | 3 | 2004 | 681 | 0.080 |
Why?
| | Cerebral Cortex | 1 | 2013 | 467 | 0.080 |
Why?
| | DNA Primers | 2 | 2004 | 516 | 0.080 |
Why?
| | Codon | 2 | 2007 | 94 | 0.080 |
Why?
| | Exoribonucleases | 1 | 2010 | 46 | 0.070 |
Why?
| | Mutagenesis | 2 | 2008 | 191 | 0.070 |
Why?
| | Uracil | 1 | 2008 | 35 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 100 | 0.070 |
Why?
| | Cytosine | 1 | 2008 | 49 | 0.070 |
Why?
| | Base Pairing | 1 | 2008 | 65 | 0.070 |
Why?
| | Adenine Nucleotides | 1 | 2008 | 21 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2014 | 1128 | 0.070 |
Why?
| | Oligoribonucleotides | 1 | 2008 | 52 | 0.070 |
Why?
| | Puromycin | 2 | 1999 | 10 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 2030 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 152 | 0.070 |
Why?
| | Cognition | 1 | 2016 | 1252 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4211 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 2 | 2008 | 477 | 0.070 |
Why?
| | RNA Caps | 2 | 2012 | 33 | 0.060 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2008 | 176 | 0.060 |
Why?
| | Depression | 1 | 2016 | 1520 | 0.060 |
Why?
| | Transdermal Patch | 1 | 2025 | 14 | 0.060 |
Why?
| | Administration, Cutaneous | 1 | 2025 | 128 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 699 | 0.060 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2005 | 100 | 0.060 |
Why?
| | Selection, Genetic | 1 | 2007 | 258 | 0.060 |
Why?
| | Sequence Deletion | 2 | 2004 | 194 | 0.060 |
Why?
| | Diffuse Axonal Injury | 1 | 2024 | 8 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2012 | 1170 | 0.050 |
Why?
| | Phylogeny | 1 | 2008 | 1011 | 0.050 |
Why?
| | Cytoplasm | 1 | 2004 | 270 | 0.050 |
Why?
| | Quality of Life | 1 | 2016 | 3142 | 0.050 |
Why?
| | Antivenins | 1 | 2023 | 29 | 0.050 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2023 | 55 | 0.050 |
Why?
| | Pain Measurement | 1 | 2025 | 550 | 0.050 |
Why?
| | Horses | 1 | 2023 | 204 | 0.050 |
Why?
| | Capsid | 1 | 2002 | 94 | 0.040 |
Why?
| | Craniocerebral Trauma | 2 | 2016 | 175 | 0.040 |
Why?
| | Poly G | 1 | 2001 | 2 | 0.040 |
Why?
| | Patients | 1 | 2023 | 179 | 0.040 |
Why?
| | Precipitin Tests | 1 | 2001 | 95 | 0.040 |
Why?
| | Risk Factors | 1 | 2016 | 10623 | 0.040 |
Why?
| | Medical Audit | 2 | 1991 | 76 | 0.040 |
Why?
| | Interferons | 1 | 2002 | 193 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1833 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2002 | 782 | 0.040 |
Why?
| | Anisomycin | 1 | 1999 | 7 | 0.040 |
Why?
| | Ricin | 1 | 1999 | 8 | 0.040 |
Why?
| | Cycloheximide | 1 | 1999 | 47 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 1999 | 18 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 695 | 0.040 |
Why?
| | Phosphorylation | 1 | 2024 | 1761 | 0.040 |
Why?
| | Diphtheria Toxin | 1 | 1999 | 65 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1999 | 49 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 387 | 0.040 |
Why?
| | Apolipoprotein E3 | 1 | 2018 | 3 | 0.040 |
Why?
| | Protein Domains | 1 | 2020 | 313 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2002 | 511 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2018 | 136 | 0.030 |
Why?
| | Inflammation | 2 | 2020 | 2893 | 0.030 |
Why?
| | Unconsciousness | 1 | 2016 | 22 | 0.030 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1996 | 24 | 0.030 |
Why?
| | Fluoresceins | 1 | 2016 | 48 | 0.030 |
Why?
| | Subcellular Fractions | 1 | 1996 | 75 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 88 | 0.030 |
Why?
| | Maze Learning | 1 | 2016 | 106 | 0.030 |
Why?
| | Indicators and Reagents | 1 | 1996 | 107 | 0.030 |
Why?
| | Cytidine Triphosphate | 1 | 1995 | 19 | 0.030 |
Why?
| | Guanidines | 1 | 1995 | 41 | 0.030 |
Why?
| | Golgi Apparatus | 1 | 2016 | 102 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2340 | 0.030 |
Why?
| | Amyloid | 1 | 2016 | 95 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 330 | 0.030 |
Why?
| | Point Mutation | 1 | 1996 | 245 | 0.030 |
Why?
| | tau Proteins | 1 | 2016 | 101 | 0.030 |
Why?
| | Immunoblotting | 1 | 1995 | 307 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1996 | 543 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 567 | 0.030 |
Why?
| | Methionine | 1 | 1995 | 163 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 925 | 0.030 |
Why?
| | Peptides | 1 | 1999 | 986 | 0.030 |
Why?
| | Hospitals, Teaching | 2 | 1991 | 115 | 0.030 |
Why?
| | Dentate Gyrus | 1 | 2013 | 40 | 0.030 |
Why?
| | Coloring Agents | 1 | 2013 | 93 | 0.020 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2013 | 77 | 0.020 |
Why?
| | Azepines | 1 | 2013 | 106 | 0.020 |
Why?
| | Poliomyelitis | 1 | 1993 | 35 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2182 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 168 | 0.020 |
Why?
| | District of Columbia | 1 | 2012 | 35 | 0.020 |
Why?
| | Functional Laterality | 1 | 2013 | 241 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 515 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1122 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1355 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2948 | 0.020 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2012 | 17 | 0.020 |
Why?
| | Ambulances | 1 | 2012 | 53 | 0.020 |
Why?
| | Rhinovirus | 1 | 2012 | 57 | 0.020 |
Why?
| | Octoxynol | 1 | 1991 | 13 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 856 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 1991 | 40 | 0.020 |
Why?
| | Deoxycholic Acid | 1 | 1991 | 15 | 0.020 |
Why?
| | Escherichia coli | 1 | 1996 | 849 | 0.020 |
Why?
| | Methylation | 1 | 2012 | 243 | 0.020 |
Why?
| | Detergents | 1 | 1991 | 44 | 0.020 |
Why?
| | Virulence | 1 | 2012 | 271 | 0.020 |
Why?
| | DEAD Box Protein 58 | 1 | 2010 | 7 | 0.020 |
Why?
| | Solubility | 1 | 1991 | 239 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 832 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11460 | 0.020 |
Why?
| | DEAD-box RNA Helicases | 1 | 2010 | 90 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2010 | 379 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2010 | 207 | 0.020 |
Why?
| | Chick Embryo | 1 | 1988 | 134 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 380 | 0.020 |
Why?
| | Brain Concussion | 1 | 2016 | 633 | 0.020 |
Why?
| | Hippocampus | 1 | 2013 | 968 | 0.020 |
Why?
| | Hospital Mortality | 1 | 1991 | 975 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 600 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 1991 | 638 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4553 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2012 | 3120 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2010 | 853 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2010 | 1182 | 0.010 |
Why?
| | Fibroblasts | 1 | 1988 | 1035 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 3609 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 2002 | 223 | 0.010 |
Why?
| | Surface Properties | 1 | 2002 | 411 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 1991 | 2266 | 0.010 |
Why?
| | Brefeldin A | 1 | 1997 | 9 | 0.010 |
Why?
| | Oximes | 1 | 1997 | 26 | 0.010 |
Why?
| | Cyclopentanes | 1 | 1997 | 19 | 0.010 |
Why?
| | Genetic Techniques | 1 | 1997 | 67 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1997 | 187 | 0.010 |
Why?
| | Sulfonamides | 1 | 1997 | 574 | 0.010 |
Why?
| | Reading Frames | 1 | 1992 | 3 | 0.010 |
Why?
| | Helper Viruses | 1 | 1992 | 3 | 0.010 |
Why?
| | Virion | 1 | 1992 | 115 | 0.010 |
Why?
| | England | 1 | 1991 | 109 | 0.010 |
Why?
| | Peer Review | 1 | 1991 | 45 | 0.010 |
Why?
| | Trauma Severity Indices | 1 | 1991 | 110 | 0.010 |
Why?
| | Transfection | 1 | 1992 | 952 | 0.000 |
Why?
| | United Kingdom | 1 | 1991 | 332 | 0.000 |
Why?
| | Central Nervous System | 1 | 1991 | 272 | 0.000 |
Why?
| | Aged, 80 and over | 2 | 1991 | 8130 | 0.000 |
Why?
| | Infant | 2 | 1991 | 9886 | 0.000 |
Why?
| | Survival Rate | 1 | 1991 | 2035 | 0.000 |
Why?
| | Child, Preschool | 2 | 1991 | 11631 | 0.000 |
Why?
| | Child | 2 | 1991 | 22441 | 0.000 |
Why?
|
|
Barton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|